1. Home
  2. PSTL vs GYRE Comparison

PSTL vs GYRE Comparison

Compare PSTL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Postal Realty Trust Inc.

PSTL

Postal Realty Trust Inc.

HOLD

Current Price

$23.89

Market Cap

554.6M

Sector

Real Estate

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.09

Market Cap

624.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSTL
GYRE
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
554.6M
624.9M
IPO Year
2018
2004

Fundamental Metrics

Financial Performance
Metric
PSTL
GYRE
Price
$23.89
$6.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$20.19
$17.00
AVG Volume (30 Days)
282.8K
66.5K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
4.62%
N/A
EPS Growth
123.81
N/A
EPS
0.11
N/A
Revenue
$95,823,000.00
$275,000.00
Revenue This Year
$18.01
$19.88
Revenue Next Year
$11.38
N/A
P/E Ratio
$214.86
N/A
Revenue Growth
25.47
N/A
52 Week Low
$13.17
$5.97
52 Week High
$23.87
$11.61

Technical Indicators

Market Signals
Indicator
PSTL
GYRE
Relative Strength Index (RSI) 69.61 32.79
Support Level $22.15 N/A
Resistance Level $23.87 $8.26
Average True Range (ATR) 0.67 0.38
MACD -0.02 -0.15
Stochastic Oscillator 93.85 4.34

Price Performance

Historical Comparison
PSTL
GYRE

About PSTL Postal Realty Trust Inc.

Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: